X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs PANACEA BIOTECH - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA PANACEA BIOTECH ABBOTT INDIA/
PANACEA BIOTECH
 
P/E (TTM) x 32.8 84.6 38.8% View Chart
P/BV x 8.2 1.9 436.3% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 ABBOTT INDIA   PANACEA BIOTECH
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-16
PANACEA BIOTECH
Mar-14
ABBOTT INDIA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs6,015149 4,045.1%   
Low Rs3,70782 4,504.3%   
Sales per share (Unadj.) Rs1,236.984.1 1,470.0%  
Earnings per share (Unadj.) Rs122.2-18.3 -667.4%  
Cash flow per share (Unadj.) Rs129.0-6.7 -1,925.3%  
Dividends per share (Unadj.) Rs35.000-  
Dividend yield (eoy) %0.70-  
Book value per share (Unadj.) Rs521.283.7 622.7%  
Shares outstanding (eoy) m21.2561.25 34.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.91.4 286.3%   
Avg P/E ratio x39.8-6.3 -630.6%  
P/CF ratio (eoy) x37.7-17.2 -218.6%  
Price / Book Value ratio x9.31.4 675.9%  
Dividend payout %28.60-   
Avg Mkt Cap Rs m103,2967,074 1,460.1%   
No. of employees `0003.02.8 107.5%   
Total wages/salary Rs m3,3701,449 232.5%   
Avg. sales/employee Rs Th8,891.81,874.1 474.5%   
Avg. wages/employee Rs Th1,140.0527.0 216.3%   
Avg. net profit/employee Rs Th878.3-407.7 -215.4%   
INCOME DATA
Net Sales Rs m26,2845,154 510.0%  
Other income Rs m504100 505.4%   
Total revenues Rs m26,7895,254 509.9%   
Gross profit Rs m3,665-766 -478.3%  
Depreciation Rs m144711 20.3%   
Interest Rs m81,503 0.5%   
Profit before tax Rs m4,017-2,881 -139.5%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m1,42117 8,458.3%   
Profit after tax Rs m2,596-1,121 -231.5%  
Gross profit margin %13.9-14.9 -93.8%  
Effective tax rate %35.4-0.6 -6,064.8%   
Net profit margin %9.9-21.8 -45.4%  
BALANCE SHEET DATA
Current assets Rs m14,4463,810 379.1%   
Current liabilities Rs m4,7258,365 56.5%   
Net working cap to sales %37.0-88.4 -41.8%  
Current ratio x3.10.5 671.3%  
Inventory Days Days51156 33.0%  
Debtors Days Days2067 29.1%  
Net fixed assets Rs m1,11314,480 7.7%   
Share capital Rs m21361 346.7%   
"Free" reserves Rs m10,808903 1,196.8%   
Net worth Rs m11,0765,127 216.0%   
Long term debt Rs m05,832 0.0%   
Total assets Rs m16,24119,433 83.6%  
Interest coverage x497.0-0.9 -54,224.0%   
Debt to equity ratio x01.1 0.0%  
Sales to assets ratio x1.60.3 610.3%   
Return on assets %16.02.0 816.4%  
Return on equity %23.4-21.9 -107.2%  
Return on capital %36.33.6 999.4%  
Exports to sales %0.624.5 2.5%   
Imports to sales %12.610.2 124.1%   
Exports (fob) Rs m1621,264 12.8%   
Imports (cif) Rs m3,322525 633.1%   
Fx inflow Rs m2681,539 17.4%   
Fx outflow Rs m3,927942 416.9%   
Net fx Rs m-3,659597 -612.8%   
CASH FLOW
From Operations Rs m2,514599 419.6%  
From Investments Rs m-800-438 182.6%  
From Financial Activity Rs m-803-303 265.3%  
Net Cashflow Rs m912-141 -645.4%  

Share Holding

Indian Promoters % 0.0 74.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 0.6 1,316.7%  
FIIs % 0.1 1.3 7.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 23.6 72.5%  
Shareholders   18,270 10,259 178.1%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   J.B.CHEMICALS  SUVEN LIFE  CIPLA  CADILA HEALTHCARE  VENUS REMEDIES  

Compare ABBOTT INDIA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Aug 18, 2017 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - DR. REDDYS LAB COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS